Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Items 101–200 of 1,000
Li, X., Warmington, K. S., Niu, Q.-T., Asuncion, F. J., Barrero, M., Grisanti, M., Dwyer, D., Stouch, B., Thway, T. M., Stolina, M., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.182 · Cited by 231
Regulation of circulating sclerostin levels by sex steroids in women and in men
Mödder, U. I., Clowes, J. A., Hoey, K., Peterson, J. M., McCready, L., Oursler, M. J., Riggs, B. L., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.128 · Cited by 229
The natural history of sclerosteosis
Hamersma, H., Gardner, J., & Beighton, P. (2003) · Clinical Genetics · doi:10.1034/j.1399-0004.2003.00036.x · Cited by 231
Self-citationAvsian-Kretchmer, O., & Hsueh, A. J. W. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0227 · Cited by 229
“placenta, and fetal skin in human and mouse (59).”
BackgroundThe WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
ten Dijke, P., Krause, C., de Gorter, D. J. J., Löwik, C. W. G. M., & van Bezooijen, R. L. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01183 · Cited by 224
The two faces of serotonin in bone biology
Ducy, P., & Karsenty, G. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201006123 · Cited by 210
“…Sclerostin (SOST), whose absence in Van Buchem patients (or mice) cause high bone mass but also skeleton overgrowth, hearing loss, and hyperostosis (Brunkow et al., 2001; van Bezooijen et al., 2005; Li et al., 2008), HBM patients do not develop overt deleterious phenotypes; an observation that…”
The mutational spectrum of human malignant autosomal recessive osteopetrosis
Sobacchi, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1767 · Cited by 226
“In addition, the molecular basis of other sclerotizing bone diseases such as sclerosteosis, a disease unusually frequent in the Afrikaner population of South Africa (OMIM 269500), has also been recently clarified (29,30).”
BackgroundLRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST
Semenov, M. V., & He, X. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609509200 · Cited by 222
Wnt Signaling: A Key Regulator of Bone Mass
Baron, R., Rawadi, G., & Roman‐Roman, S. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76004-5 · Cited by 219
The chronic kidney disease — Mineral bone disorder (CKD-MBD): Advances in pathophysiology
Hruska, K. A., Sugatani, T., Agapova, O., & Fang, Y. (2017) · Bone · doi:10.1016/j.bone.2017.01.023 · Cited by 214
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
“Loss-of-function mutation or deletion in the SOST gene occurs in patients with sclerosing skeletal dysplasias, such as craniodiaphyseal dysplasia (68), sclerosteosis (69) and van Buchem disease (70).”
BackgroundInternational nosology and classification of constitutional disorders of bone (2001)
Hall, C. M. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10828 · Cited by 221
Interaction between osteoblast and osteoclast: impact in bone disease.
Phan, T. C. A., Xu, J., & Zheng, M. (2004) · PubMed · doi:10.14670/hh-19.1325 · Cited by 206
Wnt Signaling and the Control of Human Stem Cell Fate
Van Camp, J. K., Beckers, S., Zegers, D., & Van Hul, W. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9486-8 · Cited by 196
The Impact of Diabetes and Diabetes Medications on Bone Health
Gilbert, M. P., & Pratley, R. E. (2015) · Endocrine Reviews · doi:10.1210/er.2012-1042 · Cited by 209
LRP5 and Wnt Signaling: A Union Made for Bone
Johnson, M. L., Harnish, K., Nusse, R., & Van Hul, W. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040816 · Cited by 212
Choi, H. Y., Dieckmann, M., Herz, J., & Niemeier, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007930 · Cited by 208
“Mutations in SOST cause the human disease sclerosteosis, which is characterized by massive bone overgrowth [28,29].”
BackgroundBasic Biology of Skeletal Aging: Role of Stress Response Pathways
Almeida, M., & O'Brien, C. A. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt079 · Cited by 201
Regulation of bone metabolism by Wnt signals
Kobayashi, Y., Uehara, S., Udagawa, N., & Takahashi, N. (2016) · Journal of Biochemistry · doi:10.1093/jb/mvv124 · Cited by 200
Molecular mechanisms and clinical management of cancer bone metastasis
Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 193
“Another inhibitor of WNT signaling is SOST, the functional loss of which may lead to multiple bone disorders due to dysregulation of bone remodeling.(195,196) Sclerostin, known as the protein product of the SOST gene, can inhibit canonical WNT signaling(197,198) and thus promote bone formation.”
BackgroundControlling cell fate by bone morphogenetic protein receptors
ten Dijke, P., Korchynskyi, O., Valdimarsdottir, G., & Goumans, M.-J. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.09.016 · Cited by 202
Wnt Signaling in Bone Development and Disease: Making Stronger Bone with Wnts
Regard, J. B., Zhong, Z., Williams, B. O., & Yang, Y. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007997 · Cited by 197
“Mutations in the secreted Wnt/b-catenin signaling antagonist sclerostin (SOST) cause two overlapping diseases: sclerosteosis and van Buchem disease (Balemans et al. 2001, 2002; Brunkow et al. 2001).”
BackgroundInoue, K., Mikuni-Takagaki, Y., Oikawa, K., Itoh, T., Inada, M., Noguchi, T., Park, J.-S., Onodera, T., Krane, S. M., Noda, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607290200 · Cited by 198
A Review of Osteocyte Function and the Emerging Importance of Sclerostin
Compton, J. T., & Lee, F. Y. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.m.01096 · Cited by 192
Kamiya, N., Kobayashi, T., Mochida, Y., Yu, P. B., Yamauchi, M., Kronenberg, H. M., & Mishina, Y. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090806 · Cited by 198
“In humans, loss-of-function and hypomorphic mutations in SOST cause sclerosteosis((62,63)) and Van Buchem disease,((64,65)) respectively, with an HBM phenotype.”
BackgroundDeterminants of serum sclerostin in healthy pre- and postmenopausal women
Ardawi, M.-S. M., Al-Kadi, H. A., Rouzi, A. A., & Qari, M. H. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.479 · Cited by 193
Effects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
“Loss of sclerostin in humans causes the high bone mass disorders Van Buchem's disease and sclerosteosis [9,10].”
Reichenberger, E., Tiziani, V., Watanabe, S., Park, L., Ueki, Y., Santanna, C., Baur, S. T., Shiang, R., Grange, D. K., Beighton, P., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320612 · Cited by 199
“Sclerosteosis is the only disorder for which the causative gene (SOST) has been identified (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundSelf-citationLenk, G. M., Tromp, G., Weinsheimer, S., Gatalica, Z., Berguer, R., & Kuivaniemi, H. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-237 · Cited by 183
“SOST belongs to the DAN family of antagonists of the transforming growth factor-beta (TGF-β) superfamily and also antagonizes Wnt signaling [39,40].”
BackgroundWnt signaling in bone metabolism
Kubota, T., Michigami, T., & Ozono, K. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0064-8 · Cited by 180
“Loss-of-function mutations and decreased expression of the SOST gene in human are associated with sclerosteosis and van Buchem disease, respectively [59–61].”
BackgroundPadhi, D., Allison, M., Kivitz, A. J., Gutierrez, M. J., Stouch, B., Wang, C., & Jang, G. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.239 · Cited by 185
“Sclerostin was first identified as the protein that is deficient due to a null mutation of SOST in patients with sclerosteosis, a rare bone disorder associated with profoundly high bone mass.(3,4) Targeted deletion of the sclerostin gene in SOST knockout mice is associated with increased bone formation and a >50% incr…”
BackgroundSkeletal Overexpression of Gremlin Impairs Bone Formation and Causes Osteopenia
Gazzerro, E., Pereira, R. C., Jorgetti, V., Olson, S., Economides, A. N., & Canalis, E. (2005) · Endocrinology · doi:10.1210/en.2004-0766 · Cited by 182
Matrix metalloproteinases and bone
Krane, S. M., & Inada, M. (2008) · Bone · doi:10.1016/j.bone.2008.03.020 · Cited by 183
“The human disorder, sclereostosis characterized by bone overgrowth is caused by mutations in SOST [81].”
BackgroundCohen-Kfir, E., Artsi, H., Levin, A., Abramowitz, E., Bajayo, A., Gurt, I., Zhong, L., D'Urso, A., Toiber, D., Mostoslavsky, R., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1128 · Cited by 179
Sexually dimorphic gene expression in the developing mouse gonad
Menke, D. B., & Page, D. C. (2002) · Gene Expression Patterns · doi:10.1016/s1567-133x(02)00022-4 · Cited by 175
“Sostl (Sclerostin-like) is expressed in interstitial cells of the testis and is ,39% identical to the recently identified human sclerostin gene (SOST ), mutation of which results in progressive bone overgrowth (Brunkow et al., 2001).”
Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways
Krause, C., Korchynskyi, O., de Rooij, K., Weidauer, S. E., de Gorter, D. J. J., van Bezooijen, R. L., Hatsell, S., Economides, A. N., Mueller, T. D., Löwik, C. W. G. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153890 · Cited by 178
Bone Mineral Density in Sclerosteosis; Affected Individuals and Gene Carriers
Gardner, J. C., van Bezooijen, R. L., Mervis, B., Hamdy, N. A. T., Löwik, C. W. G. M., Hamersma, H., Beighton, P., & Papapoulos, S. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1235 · Cited by 178
Self-citationDisuse Osteoporosis: Clinical and Mechanistic Insights
Rolvien, T., & Amling, M. (2022) · Calcified Tissue International · doi:10.1007/s00223-021-00836-1 · Cited by 162
Controlling mesenchymal stem cell differentiation by TGFβ family members
Roelen, B. A. J., & Dijke, P. T. (2003) · Journal of Orthopaedic Science · doi:10.1007/s00776-003-0702-2 · Cited by 172
Terkawi, M. A., Matsumae, G., Shimizu, T., Takahashi, D., Kadoya, K., & Iwasaki, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031786 · Cited by 192
McColm, J., Hu, L., Womack, T., Tang, C. C., & Chiang, A. Y. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2092 · Cited by 173
“Loss‐of‐function mutations in SOST are associated with an autosomal‐recessive disorder, sclerosteosis, which is characterized by progressive bone thickening.((3,4)) Individuals with Van Buchemdisease, a recessively inherited high bonemass disorder, have a deletion downstream of the SOST gene resulting in reduced expre…”
BackgroundArdawi, M.-S. M., Akhbar, D. H., AlShaikh, A., Ahmed, M. M., Qari, M. H., Rouzi, A. A., Ali, A. Y., Abdulrafee, A. A., & Saeda, M. Y. (2013) · Bone · doi:10.1016/j.bone.2013.06.029 · Cited by 172
“signaling, osteoblastogenesis, and bone formation [10–12].”
The role of the Wnt signaling pathway in osteoblast commitment and differentiation
Yavropoulou, M., & Yovos, J. (2007) · HORMONES · doi:10.14310/horm.2002.1111024 · Cited by 166
Bone mass is inversely proportional to Dkk1 levels in mice
MacDonald, B. T., Joiner, D. M., Oyserman, S. M., Sharma, P., Goldstein, S. A., He, X., & Hauschka, P. V. (2007) · Bone · doi:10.1016/j.bone.2007.05.009 · Cited by 169
“SOST loss-of-function mutations are responsible for Sclerosteosis, a human disorder characterized by increased bone density and excessive bone overgrowth [25,26].”
BackgroundRole of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
Lewiecki, E. M. (2014) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13510479 · Cited by 160
Winkler, D. G., Sutherland, M. S. K., Ojala, E., Turcott, E., Geoghegan, J. C., Shpektor, D., Skonier, J. E., Yu, C., & Latham, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m400524200 · Cited by 164
Self-citationBMP antagonists: Their roles in development and involvement in pathophysiology
Yanagita, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.007 · Cited by 161
“The SOST gene was originally identified as the gene responsible for a progressive sclerosing bone dysplasia known as sclerosteosis, an autosomal recessive disorder [60].”
BackgroundInfluentialWnt signaling and skeletal development
Liu, F., Kohlmeier, S. E., & Wang, C.-Y. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.11.011 · Cited by 176
Emerging therapeutic opportunities for skeletal restoration
Kawai, M., Mödder, U. I., Khosla, S., & Rosen, C. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3299 · Cited by 159
Bril: A Novel Bone-Specific Modulator of Mineralization
Moffatt, P., Gaumond, M.-H., Salois, P., Sellin, K., Bessette, M.-C., Godin, É., de Oliveira, P. T., Atkins, G. J., Nanci, A., & Thomas, G. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080412 · Cited by 154
“In fact, currently, only five genes have been specifically associated with mineralizing tissue; two key transcription factors (Cbfa1((36)) and osterix((37))), two structural proteins (BSP((38)) and osteocalcin((39,40))), and the osteocyte-specific secreted protein sclerostin.((41,42)) Our characterization of FIG.”
BackgroundRole of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders
Marini, F., Giusti, F., Palmini, G., & Brandi, M. L. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06523-7 · Cited by 174
“Two autosomal recessive high bone mass disorders, caused respectively by biallelic inactivating mutations of the SOST gene [61, 62] and by a 52-kb deletion of the SOST enhancer element, have been identified in humans, i.”
BackgroundNoggin Suppression Enhances in Vitro Osteogenesis and Accelerates in Vivo Bone Formation
Wan, D. C., Pomerantz, J. H., Brunet, L. J., Kim, J.-B., Chou, Y.-F., Wu, B. M., Harland, R., Blau, H. M., & Longaker, M. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703282200 · Cited by 158
HDAC5 Controls MEF2C-Driven Sclerostin Expression in Osteocytes
Wein, M. N., Spatz, J., Nishimori, S., Doench, J., Root, D., Babij, P., Nagano, K., Baron, R., Brooks, D., Bouxsein, M., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2381 · Cited by 158
“In humans, lack of SOST owing to loss of function mutations causes high bone mass in the rare disease, sclerosteosis,((5)) whereas reduced SOST levels owing to deletion of a downstream intergenic enhancer region causes a milder high bone mass phenotype in Van Buchem disease.”
BackgroundSclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2
Kogawa, M., Wijenayaka, A. R., Ormsby, R. T., Thomas, G. P., Anderson, P. H., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2003 · Cited by 153
“Mutations of the SOST gene have been identified as causative in sclerosteosis, a high bone mass disease in humans.((3,4)) A 52‐kb deletion of a regulatory region approximately 35 kb distal to the SOST gene is causative of the high bone mass phenotype seen in Van Buchem’s disease.”
BackgroundEttenberg, S. A., Charlat, O., Daley, M. P., Liu, S., Vincent, K. J., Stuart, D. D., Schuller, A. G., Yuan, J., Ospina, B., Green, J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007428107 · Cited by 150
“Wnt signaling promotes bone formation by increasing the growth and differentiation of osteoblasts (19), and in humans, gain-of-function mutations of LRP5 (10, 20) and lossof-function mutations of Wnt antagonist SOST (21, 22) lead to high bone-mass diseases.”
BackgroundCejka, D., Jäger-Lansky, A., Kieweg, H., Weber, M., Bieglmayer, C., Haider, D. G., Diarra, D., Patsch, J., Kainberger, F. M., Bohle, B., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr270 · Cited by 158
The Binding Between Sclerostin and LRP5 is Altered by DKK1 and by High-Bone Mass LRP5 Mutations
Balemans, W., Piters, E., Cleiren, E., Ai, M., Wesenbeeck, L. V., Warman, M. L., & Hul, W. V. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9130-9 · Cited by 160
“Lossof-function mutations in SOST (the gene encoding sclerostin) cause sclerosteosis and van Buchem disease, two similar types of autosomal recessive craniotubular hyperostosis [26–29].”
BackgroundArdawi, M.-S. M., Rouzi, A. A., Al-Sibiani, S. A., Al-Senani, N. S., Qari, M. H., & Mousa, S. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1718 · Cited by 143
“In the Cox model, the followup time describes the time from baseline visit to either (1) the first fracture or (2) the completion of the follow-up period, or (3) to death if no fracture had occurred.”
MethodSclerostin antibody treatment enhances metaphyseal bone healing in rats
Agholme, F., Li, X., Isaksson, H., Ke, H. Z., & Aspenberg, P. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.135 · Cited by 142
“Mutations of the SOST gene cause high bone mass in humans.((6,7)) Similarly, a high-bone-mass phenotype is replicated in SOST knockout mice.”
BackgroundLrp5 and Lrp6 redundantly control skeletal development in the mouse embryo
Joeng, K. S., Schumacher, C. A., Zylstra-Diegel, C. R., Long, F., & Williams, B. O. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.08.020 · Cited by 148
“…proteins that participate in Wnt signaling have also been implicated in postnatal bone formation, including the extracellular Wnt antagonist sclerostin (Balemans et al., 2001; Balemans et al., 2002; Brunkow et al., 2001; Li et al., 2008; Semenov et al., 2005), and Wnt10b (Bennett et al., 2005).”
BackgroundGLASER, D. L., ECONOMIDES, A. N., WANG, L., LIU, X., KIMBLE, R. D., FANDL, J. P., WILSON, J. M., STAHL, N., KAPLAN, F. S., & SHORE, E. M. (2003) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200312000-00010 · Cited by 145
USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney
Yanagita, M., Oka, M., Watabe, T., Iguchi, H., Niida, A., Takahashi, S., Akiyama, T., Miyazono, K., Yanagisawa, M., & Sakurai, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.075 · Cited by 144
The Role of Osteocytes in Age-Related Bone Loss
Jilka, R. L., & O’Brien, C. A. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0297-0 · Cited by 145
Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction
Wehmeyer, C., Frank, S., Beckmann, D., Böttcher, M., Cromme, C., König, U., Fennen, M., Held, A., Paruzel, P., Hartmann, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4351 · Cited by 138
“Scien expression results in a high bone mass and increased bone strength as is seen in patients with sclerosteosis (16) and Van Buchem disease (17, 18) as well as in sclerostin-deficient mice (19, 20).”
BackgroundSclerostin expression and functions beyond the osteocyte
Weivoda, M. M., Youssef, S. J., & Oursler, M. J. (2016) · Bone · doi:10.1016/j.bone.2016.11.024 · Cited by 149
“Consistent with RNA data showing cartilage expression of SOST [2], Winkler, et al.”
BackgroundResultInfluentialThe Wnt signaling pathway and bone metabolism
Johnson, M. L., & Kamel, M. A. (2007) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32816e06f9 · Cited by 151
Renal Elimination of Sclerostin Increases With Declining Kidney Function
Cejka, D., Marculescu, R., Kozakowski, N., Plischke, M., Reiter, T., Gessl, A., & Haas, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2786 · Cited by 139
Targeted deletion of Sost distal enhancer increases bone formation and bone mass
Collette, N. M., Genetos, D. C., Economides, A. N., Xie, L., Shahnazari, M., Yao, W., Lane, N. E., Harland, R. M., & Loots, G. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207188109 · Cited by 130
Sclerostin in Mineralized Matrices and van Buchem Disease
van Bezooijen, R. L., Bronckers, A. L., Gortzak, R. A., Hogendoorn, P. C. W., van der Wee-Pals, L., Balemans, W., Oostenbroek, H. J., Van Hul, W., Hamersma, H., Dikkers, F. G., et al. (2009) · Journal of Dental Research · doi:10.1177/0022034509338340 · Cited by 138
“…generalized osteo sclerosis due to increased osteoblastic activity without any evidence of hor monal abnormalities (van Buchem et al., 1955; Truswell, 1958; Epstein et al., 1979; Balemans et al., 2001, 2002; Brunkow et al., 2001; StaehlingHampton et al., 2002; and our own unpublished observations).”
BackgroundSelf-citationMolecular Genetic Studies of Gene Identification for Osteoporosis: A 2004 Update
Liu, Y., Shen, H., Xiao, P., Xiong, D.-H., Li, L.-H., Recker, R. R., & Deng, H. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051002 · Cited by 144
“SOST is a disease-causing gene for sclerostenosis, a sclerosing bone dysplasia characterized by hyperostosis and overgrowth of normal bone tissue.((101)) In a case-control study of 619 Scottish women with either high or low BMD”
Backgroundvan Lierop, A. H., Hamdy, N. A., Hamersma, H., van Bezooijen, R. L., Power, J., Loveridge, N., & Papapoulos, S. E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.474 · Cited by 133
“, Helensvale, Australia), focusing on the presence of a single cysteine to tyrosine substitution 69 base pairs downstream of the predicted translation initiation site (C69T), previously found to be the underlying mutation in South African patients with sclerosteosis.((3))”
BackgroundSelf-citationDNA methylation contributes to the regulation of sclerostin expression in human osteocytes
Delgado‐Calle, J., Sañudo, C., Bolado‐Carrancio, A., Fernández, A. F., Arozamena, J., Pascual-Carra, M. A., Rodríguez-Rey, J. C., Fraga, M. F., Bonewald, L. F., & Riancho, J. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1491 · Cited by 143
“In fact, functional mutations of the SOST gene cause abnormal skeletal phenotypes in humans, characterized by high bone mineral density.((9,10))”
BackgroundStructural and Functional Studies of LRP6 Ectodomain Reveal a Platform for Wnt Signaling
Chen, S., Bubeck, D., MacDonald, B. T., Liang, W.-X., Mao, J.-H., Malinauskas, T., Llorca, O., Aricescu, A. R., Siebold, C., He, X., et al. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.09.007 · Cited by 136
“LRP5/LRP6 antagonists are either directly involved in human diseases, as in the case of SOST (Balemans et al., 2002; Brunkow et al., 2001) or are promising therapeutic targets as in the case of both DKK1 and SOST (MacDonald et al.”
BackgroundInfluentialJohnson, M. L., & Rajamannan, N. M. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-006-9003-3 · Cited by 155
“SOST mutations, for example, have been shown to results in the high bone mass phenotype, sclerosteosis [98, 99].”
BackgroundYoulten, S. E., Kemp, J. P., Logan, J. G., Ghirardello, E. J., Sergio, C. M., Dack, M. R. G., Guilfoyle, S. E., Leitch, V. D., Butterfield, N. C., Komla-Ebri, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22517-1 · Cited by 133
Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in Glucose Homeostasis
Jin, T. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1146 · Cited by 146
Maupin, K. A., Droscha, C. J., & Williams, B. O. (2013) · Bone Research · doi:10.4248/br201301004 · Cited by 142
Uitterlinden, A. G., Arp, P., Paeper, B. W., Charmley, P., Proll, S. C., Rivadeneira, F., Fang, Y., van Meurs, J. B. J., Britschgi, T. B., Latham, J. A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426458 · Cited by 144
“The gene that encodes sclerostin, or SOST, is mutated in the disorder sclerosteosis (SCL [MIM 269500]), which is characterized by massive, progressive bone overgrowth throughout life (Hansen 1967; Beighton 1988; Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundInfluentialSelf-citationBone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications
Shim, J., Stavre, Z., & Gravallese, E. M. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0373-1 · Cited by 140
Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts
Kim, S. W., Lu, Y., Williams, E. A., Lai, F., Lee, J. Y., Enishi, T., Balani, D. H., Ominsky, M. S., Ke, H. Z., Kronenberg, H. M., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3038 · Cited by 128
Piters, E., Boudin, E., & Hul, W. V. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.006 · Cited by 149
Intercellular Cross-Talk Among Bone Cells: New Factors and Pathways
Sims, N. A., & Walsh, N. C. (2012) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0096-1 · Cited by 140
Ardawi, M.-S. M., Rouzi, A. A., & Qari, M. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3361 · Cited by 125
Wnt signaling and the regulation of bone mass
Baron, R., & Rawadi, G. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0006-0 · Cited by 137
“Genetic analysis demonstrated that sclerosteosis results from loss of function of the Sost gene product [ 55 ,56], whereas van Buchem’s syndrome is associated with downregulation of the expression of the Sost gene due to a partial deletion of the regulatory region downstream of Sost [11,12].”
BackgroundFei, Y., Xiao, L., Doetschman, T., Coffin, D. J., & Hurley, M. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274910 · Cited by 120
Chang, M.-K., Kramer, I., Huber, T., Kinzel, B., Guth-Gundel, S., Leupin, O., & Kneissel, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413828111 · Cited by 120
“Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone.”
BackgroundInfluentialvan Lierop, A. H., Hamdy, N. A., van Egmond, M. E., Bakker, E., Dikkers, F. G., & Papapoulos, S. E. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1794 · Cited by 124
Ryan, Z. C., Ketha, H., McNulty, M. S., McGee-Lawrence, M., Craig, T. A., Grande, J. P., Westendorf, J. J., Singh, R. J., & Kumar, R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221255110 · Cited by 123
“Inactivating mutations in the human sclerostin gene (SOST) are associated with sclerosteosis (Mendelian Inheritance in Man, MIM 269500) or van Buchem disease (MIM 239100) (6), both of which are characterized by progressive overgrowth and sclerosis of the axial and appendicular skeleton and an increase in bone mineral…”
BackgroundOsteogenesis imperfecta and therapeutics
Morello, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.010 · Cited by 135
TGF-β Family Signaling in Connective Tissue and Skeletal Diseases
MacFarlane, E. G., Haupt, J., Dietz, H. C., & Shore, E. M. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022269 · Cited by 115
Osteoporosis and Bone Mass Disorders: From Gene Pathways to Treatments
Rivadeneira, F., & Mäkitie, O. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.006 · Cited by 132
WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders
Huybrechts, Y., Mortier, G. R., Boudin, E., & Hul, W. V. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00165 · Cited by 140
“Hence, sclerostin functions as a key regulator in bone metabolism and, particularly, bone formation (46, 50).”
BackgroundIs Wnt signalling the final common pathway leading to bone formation?
Milat, F., & Ng, K. W. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.06.002 · Cited by 131
The roles of osteocytes in alveolar bone destruction in periodontitis
Huang, X., Xie, M., Xie, Y., Feng, M., Lu, X., Li, X., & Chen, L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02664-7 · Cited by 134
“Sclerosteosis and van Buchem disease [61, 62], both caused by an absence of sclerostin, lead to excessive bone growth.”
BackgroundLintern, K. B., Guidato, S., Rowe, A., Saldanha, J. W., & Itasaki, N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025478 · Cited by 121
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
Appelman‐Dijkstra, N. M., & Papapoulos, S. E. (2015) · Drugs · doi:10.1007/s40265-015-0417-7 · Cited by 128
“SOST has been identified in the kidney, liver, and heart, but sclerostin expression has not been identified in any of these tissues in humans [45, 47, 48].”
BackgroundSclerostin antibody stimulates bone regeneration after experimental periodontitis
Taut, A. D., Jin, Q., Chung, J., Galindo‐Moreno, P., Yi, E., Sugai, J. V., Ke, H. Z., Liu, M., & Giannobile, W. V. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1984 · Cited by 127
Sclerostin: A gem from the genome leads to bone-building antibodies
Pászty, C., Turner, C. H., & Robinson, M. K. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.161 · Cited by 127
“,((7,8)) and from Wim Van Hul’s group at the University of Antwerp,((9)) that sclerosteosis was caused by mutations in a single gene (SOST) encoding a novel secreted protein.”
Background
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.